35710-17-9

Upstream product

• 118-92-3 anthranilic acid 
• 75541-83-2 methyl 2‐(4‐fluorobenzamido)benzoate 
• 134-20-3 2-carbomethoxyaniline 
• 403-43-0 4-fluorobenzoyl chloride 
• 18600-51-6 2-(4-fluorophenyl)-4H-benzo[d][1,3]oxazin-4-one 

Downstream Products

• 388106-35-2 3-amino-2-(4-fluorophenyl)quinazolin-4(3H)-one 
• 389576-52-7 3-(4-bromobenzylamino)-2-(4-fluorophenyl)quinazolin-4(3H)-one 
• 1029982-40-8 3-((4-bromobenzyl)(ethyl)amino)-2-(4-fluorophenyl)quinazolin-4(3H)-one 
• 309925-98-2 4-bromo-N-[2-(4-fluoro-phenyl)-4-oxo-4H-quinazolin-3-yl]-benzamide 

Relevant academic research and scientific papers

Mononuclear Co(III), Ni(II) and Cu(II) complexes of tridentate di-tert-butylphenylhydrazone: Synthesis, characterization, X-ray crystal structures, Hirshfeld surface analysis, molecular docking and in vivo anti-inflammatory activity

A new hydrazone (LH2) derived from the condensation of 2-(4-fluorobenzamido)benzohydrazide with 3,5-di-tert-butyl-2-hydroxybenzaldehyde was used to synthesize Co(III), Ni(II) and Cu(II) complexes. These were characterized using various physicochemical, thermal, spectroscopic and single-crystal X-ray diffraction techniques. All the complexes crystallize in a monoclinic crystal system with P21/n space group and Z = 4. Structural studies of [Co(L)(LH)]?H2O indicate the presence of both amido and imidol tautomeric forms of the ligand, resulting in a distorted octahedral geometry around the Co(III) ion. On the other hand, in the [Ni(L)(DMF)] and [Cu(L)(H2O)] complexes, the ligand coordinates to the metal through imidol form resulting in distorted square planar geometry, in which the fourth position is occupied by the oxygen of coordinated DMF in [Ni(L)(DMF)] and by a water molecule in [Cu(L)(H2O)]. Hirshfeld surface calculations were performed to explore hydrogen bonding and C―H???π interactions. Molecular docking studies were carried out to study the interaction between the synthesized compounds and proteins (cyclooxygenase-2 and 5-lipoxygenase). The complexes along with the parent ligand were screened for their in vivo anti-inflammatory activity, using the carrageenan-induced rat paw oedema method. The complexes show significant anti-inflammatory potencies.

QUINAZOLINONE MODULATORS OF TGR5

The present invention relates to quinazolinone compounds useful as modulators of TGR5 and methods for the treatment or prevention of metabolic, cardiovascular, and inflammatory diseases.

QUINAZOLINONE MODULATORS OF TGR5

The present invention relates to quinazolinone compounds useful as modulators of TGR5 and methods for the treatment or prevention of metabolic, cardiovascular, and inflammatory diseases.